{"id":"https://openalex.org/W2553380403","doi":"https://doi.org/10.1182/blood.v110.11.4763.4763","title":"High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib.","display_name":"High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib.","publication_year":2007,"publication_date":"2007-11-16","ids":{"openalex":"https://openalex.org/W2553380403","doi":"https://doi.org/10.1182/blood.v110.11.4763.4763","mag":"2553380403"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v110.11.4763.4763","doi":"https://doi.org/10.1182/blood.v110.11.4763.4763","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v110.11.4763.4763","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026551753","display_name":"Hadi Danaee","orcid":"https://orcid.org/0000-0003-1225-1301","observed_orcids":["https://orcid.org/0000-0003-1225-1301"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Hadi Danaee","raw_affiliation_strings":["Millennium Pharmaceuticals Inc., Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals Inc., Boston, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090714624","display_name":"Barb Bryant","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Barb Bryant","raw_affiliation_strings":["Millennium Pharmaceuticals Inc., Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals Inc., Boston, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061190602","display_name":"Steve Roels","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I908450791","display_name":"Helicos Biosciences (United States)","ror":"https://ror.org/044cqax96","country_code":"US","type":"company","lineage":["https://openalex.org/I908450791"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Steve Roels","raw_affiliation_strings":["Helicos BioSciences Corporation, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Helicos BioSciences Corporation, Cambridge, MA, USA","institution_ids":["https://openalex.org/I908450791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056718945","display_name":"Dave Lichter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Dave Lichter","raw_affiliation_strings":["Millennium Pharmaceuticals Inc., Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals Inc., Boston, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019687444","display_name":"Eric Koening","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eric Koening","raw_affiliation_strings":["Millennium Pharmaceuticals Inc., Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals Inc., Boston, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016389673","display_name":"William L. Trepicchio","orcid":"https://orcid.org/0000-0002-9989-0183","observed_orcids":["https://orcid.org/0000-0002-9989-0183"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"William L. Trepicchio","raw_affiliation_strings":["Millennium Pharmaceuticals Inc., Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals Inc., Boston, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109292881","display_name":"Anthony L. Boral","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony Boral","raw_affiliation_strings":["Millennium Pharmaceuticals Inc., Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals Inc., Boston, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Richardson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041561666","display_name":"Yan Meng","orcid":"https://orcid.org/0000-0002-3198-8061","observed_orcids":["https://orcid.org/0000-0002-3198-8061"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Yan Meng","raw_affiliation_strings":["MGH, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MGH, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004436275","display_name":"Peter Leif Bergsagel","orcid":"https://orcid.org/0000-0003-1523-7388","observed_orcids":["https://orcid.org/0000-0003-1523-7388"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Leif Bergsagel","raw_affiliation_strings":["Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ, USA","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002972322","display_name":"Pieter Sonneveld","orcid":"https://orcid.org/0000-0002-0808-2237","observed_orcids":["https://orcid.org/0000-0002-0808-2237"]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Pieter Sonneveld","raw_affiliation_strings":["Erasmus MC, Rotterdam, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Erasmus MC, Rotterdam, Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080712446","display_name":"Annemiek Broyl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Annemiek Broyl","raw_affiliation_strings":["Erasmus MC, Rotterdam, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Erasmus MC, Rotterdam, Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012712111","display_name":"Constantine S. Mitsiades","orcid":"https://orcid.org/0000-0003-2321-8005","observed_orcids":["https://orcid.org/0000-0003-2321-8005"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Constantine Mitsiades","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066282840","display_name":"Wee Joo Chng","orcid":"https://orcid.org/0000-0003-2578-8335","observed_orcids":["https://orcid.org/0000-0003-2578-8335"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wee-Joo Chng","raw_affiliation_strings":["Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ, USA","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth Anderson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034169666","display_name":"George Mulligan","orcid":"https://orcid.org/0009-0009-5084-9604","observed_orcids":["https://orcid.org/0009-0009-5084-9604","https://orcid.org/0000-0001-8573-9434"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George Mulligan","raw_affiliation_strings":["Millennium Pharmaceuticals Inc., Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals Inc., Boston, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5016389673","https://openalex.org/A5019687444","https://openalex.org/A5026551753","https://openalex.org/A5041561666","https://openalex.org/A5056718945","https://openalex.org/A5061190602","https://openalex.org/A5080712446","https://openalex.org/A5090714624"],"corresponding_institution_ids":["https://openalex.org/I2801952686","https://openalex.org/I4210087915","https://openalex.org/I4405270001","https://openalex.org/I908450791"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.35665814,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"110","issue":"11","first_page":"4763","last_page":"4763"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9779999852180481},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.7039999961853027},{"id":"https://openalex.org/keywords/chromosomal-abnormalities","display_name":"chromosomal abnormalities","score":0.7279999852180481},{"id":"https://openalex.org/keywords/dna-copy-number-alterations","display_name":"DNA copy number alterations","score":0.7580000162124634},{"id":"https://openalex.org/keywords/hyperdiploidy","display_name":"hyperdiploidy","score":0.859000027179718},{"id":"https://openalex.org/keywords/chromosome-13-deletion","display_name":"chromosome 13 deletion","score":0.9679999947547913},{"id":"https://openalex.org/keywords/chromosome-1p-loss","display_name":"chromosome 1p deletion","score":0.8309999704360962},{"id":"https://openalex.org/keywords/chromosome-6q-deletion","display_name":"chromosome 6q deletion","score":0.9269999861717224},{"id":"https://openalex.org/keywords/chromosome-1q-amplification","display_name":"chromosome 1q amplification","score":0.9599999785423279},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.6869999766349792},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.9319999814033508},{"id":"https://openalex.org/keywords/relapsed-multiple-myeloma","display_name":"relapsed multiple myeloma","score":0.8889999985694885},{"id":"https://openalex.org/keywords/single-nucleotide-polymorphism-array","display_name":"single nucleotide polymorphism array","score":0.7990000247955322}],"concepts":[{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.8555738925933838},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.8170037269592285},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5546998977661133},{"id":"https://openalex.org/C166608930","wikidata":"https://www.wikidata.org/wiki/Q5169175","display_name":"Copy number analysis","level":5,"score":0.5249828696250916},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5179930925369263},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.49527183175086975},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4574602544307709},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4518028795719147},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.4469192326068878},{"id":"https://openalex.org/C153209595","wikidata":"https://www.wikidata.org/wiki/Q501128","display_name":"Single-nucleotide polymorphism","level":4,"score":0.42541664838790894},{"id":"https://openalex.org/C122060243","wikidata":"https://www.wikidata.org/wiki/Q7391885","display_name":"SNP array","level":5,"score":0.42133116722106934},{"id":"https://openalex.org/C139275648","wikidata":"https://www.wikidata.org/wiki/Q17134011","display_name":"SNP","level":5,"score":0.4110150635242462},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3631013035774231},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.3535587787628174},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.29470473527908325},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2758987843990326},{"id":"https://openalex.org/C141231307","wikidata":"https://www.wikidata.org/wiki/Q7020","display_name":"Genome","level":3,"score":0.2612125873565674},{"id":"https://openalex.org/C135763542","wikidata":"https://www.wikidata.org/wiki/Q106016","display_name":"Genotype","level":3,"score":0.25683674216270447},{"id":"https://openalex.org/C120821319","wikidata":"https://www.wikidata.org/wiki/Q1501491","display_name":"Copy-number variation","level":4,"score":0.24446743726730347},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.16838553547859192},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v110.11.4763.4763","doi":"https://doi.org/10.1182/blood.v110.11.4763.4763","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v110.11.4763.4763","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2589701427","https://openalex.org/W2318730183","https://openalex.org/W2245979569","https://openalex.org/W17330973","https://openalex.org/W2592323281","https://openalex.org/W2068519332","https://openalex.org/W1993745533","https://openalex.org/W1535417170","https://openalex.org/W2000189234","https://openalex.org/W1538736227"],"abstract_inverted_index":{"Abstract":[0],"Multiple":[1],"myeloma":[2,65,113,134,159,253],"is":[3,46,208],"a":[4,40,162],"disease":[5],"of":[6,28,31,51,110,139,156,168,192,231],"the":[7,13,49,59,205],"antibody":[8],"producing":[9],"plasma":[10],"cells":[11],"in":[12,35,42,64,102,133,197,219,251],"bone":[14,97],"marrow.":[15],"It":[16],"has":[17],"been":[18],"characterized":[19,165],"by":[20,166],"frequent":[21],"genomic":[22,92,127,131,180,249],"alterations":[23,33,132],"including":[24,137],"gains":[25,167,201],"and":[26,69,84,106,147,176,187,202,254],"losses":[27,203],"chromosomes.":[29],"Some":[30],"these":[32],"result":[34],"poor":[36,222],"clinical":[37,108,236],"prognosis.":[38],"Bortezomib,":[39],"first":[41],"class":[43],"proteasome":[44],"inhibitor,":[45],"approved":[47],"for":[48],"treatment":[50,70,117,258],"relapsed":[52,111,158],"multiple":[53,112,252],"myeloma.":[54],"To":[55],"better":[56],"understand":[57],"how":[58],"genome":[60,164],"wide":[61],"changes":[62],"observed":[63,218],"relate":[66],"to":[67,81,90,116,125,194,215],"prognosis":[68],"response,":[71],"we":[72],"have":[73],"used":[74],"single":[75],"nucleotide":[76],"polymorphism":[77],"(SNP)":[78],"array":[79],"technology":[80],"assess":[82,126],"genotypes":[83],"DNA":[85,94],"copy":[86],"number":[87],"at":[88,204],"up":[89],"100,000":[91],"loci.":[93],"from":[95],"147":[96],"marrow":[98],"tumor":[99],"biopsies":[100],"collected":[101],"multi-center":[103],"phase":[104],"II":[105],"III":[107],"trials":[109],"patients":[114,198,220],"prior":[115],"with":[118,199,211,221,235,257],"Bortezomib":[119],"were":[120,135],"hybridized":[121],"on":[122,149],"SNP":[123],"arrays":[124],"aberrations.":[128],"Commonly":[129],"seen":[130],"observed,":[136],"deletions":[138,181],"chromosome":[140],"13":[141,225],"(37%),":[142],"1p":[143],"(25%),":[144],"6q":[145],"(23%),":[146],"amplifications":[148],"1q":[150],"(35%).":[151],"We":[152],"found":[153],"that":[154],"35%":[155],"this":[157,243],"population":[160],"exhibited":[161],"hyperdiploid":[163],"chromosomes":[169],"3,":[170],"5,":[171],"7,":[172],"9,":[173],"11,":[174],"15,":[175],"19.":[177],"Other":[178],"notable":[179],"included":[182],"17p":[183],"(22%),":[184],"8p":[185],"(27%)":[186],"10p":[188],"(16%).":[189],"A":[190,227],"correlation":[191],"response":[193,214],"bortezomib":[195,216],"therapy":[196],"differential":[200],"chromosomal":[206],"level":[207],"ongoing.":[209],"Consistent":[210],"previous":[212],"reports,":[213],"was":[217],"prognostic":[223],"chr":[224],"deletions.":[226],"more":[228],"in-depth":[229],"analysis":[230],"specific":[232],"loci":[233],"associated":[234],"outcome":[237],"will":[238,245],"be":[239],"discussed.":[240],"In":[241],"summary,":[242],"data":[244],"help":[246],"further":[247],"define":[248],"aberrations":[250],"their":[255],"association":[256],"outcome.":[259]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2016-11-30T00:00:00"}